NBSE
NeuBase Therapeutics, Inc. Common Stock
NBSE
NBSE
Delisted
NBSE was delisted on the 10th of May, 2024.
34 hedge funds and large institutions have $1.94M invested in NeuBase Therapeutics, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 9 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
less funds holding
Funds holding: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less capital invested
Capital invested by funds: $ → $
77% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 13
Holders
34
Holding in Top 10
1
Calls
–
Puts
–
Top Buyers
| 1 | +$7.21K | |
| 2 | +$7.21K | |
| 3 | +$2K | |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$828 |
| 5 |
Wells Fargo
San Francisco,
California
|
+$762 |
Top Sellers
| 1 | -$345K | |
| 2 | -$102K | |
| 3 | -$84K | |
| 4 |
Goldman Sachs
New York
|
-$32K |
| 5 |
JAMONY
Jacob Asset Management of New York
Hermosa Beach,
California
|
-$29.9K |